Mira Pharmaceuticals Inc

Mira Pharmaceuticals Inc

Mira Pharmaceuticals Inc (ticker MIRA) is a micro‑cap biotechnology company with a market capitalisation of about $27.65 million. It focuses on early‑stage therapeutic programmes, where value is typically driven by clinical data, regulatory milestones and commercial partnerships. As a small biotech, Mira may have limited revenues and a shorter cash runway compared with larger peers, making financing rounds and partnership agreements important potential catalysts. Investors should be aware that outcomes in clinical development are uncertain: positive trial results can meaningfully re-rate a stock, while setbacks or delays can have the opposite effect. Liquidity can be low and shares may be highly volatile. Due diligence should include reading regulatory filings, investor presentations and peer‑reviewed data where available. This summary is educational only and not personalised financial advice; consider your risk tolerance and consult a regulated adviser before making investment decisions.

Stock Performance Snapshot

Strong Buy

Analyst Rating

Analysts highly recommend buying Mira Pharmaceuticals' stock with a target price of $16.5, indicating significant upside.

Average

Financial Health

Mira Pharmaceuticals has a modest book value and cash flow per share, indicating stable performance.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Baskets Featuring MIRA

Mind & Spirit

Mind & Spirit

Invest in companies transforming mental healthcare through innovative treatments and technologies. These carefully selected stocks represent leaders in psychedelic therapeutics, telehealth platforms, and neurological treatments addressing the growing global demand for mental wellness solutions.

Published: June 17, 2025

Explore Basket

Why You’ll Want to Watch This Stock

📈

Clinical Milestones Ahead

Trial readouts and regulatory progress can drive significant share moves, though outcomes are uncertain and delays common.

Funding & Dilution

Small biotechs frequently need to raise capital; fundraising terms can dilute existing shareholders and affect timelines.

🌍

Partnering Potential

Licensing or collaboration deals may validate programmes and reduce execution risk, but depend on data and negotiation outcomes.

Why invest with Nemo?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Frequently asked questions